Patents by Inventor Yasuhiro TEZUKA

Yasuhiro TEZUKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anticancer agent and side-effect-alleviating agent
    Patent number: 9907852
    Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: March 6, 2018
    Assignees: National University Corporation University of Toyama, Kracie Pharma, Ltd., National Cancer Center, Tokyo University of Science Foundation
    Inventors: Hiroyasu Esumi, Masafumi Ikeda, Katsuya Tsuchihara, Shigeki Chiba, Satoshi Yomoda, Takanori Kawashima, Toshiki Okubo, Yasuhiro Tezuka, Kenta Murata
  • ANTICANCER AGENT AND SIDE-EFFECT-ALLEVIATING AGENT
    Publication number: 20170028065
    Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.
    Type: Application
    Filed: April 10, 2015
    Publication date: February 2, 2017
    Applicants: National University Corporation University of Toyama, Kracie Pharma, Ltd., National Cancer Center, Tokyo University of Science Foundation
    Inventors: Hiroyasu Esumi, Kouji IKEDA, Katsuya TSUCHIHARA, Shigeki Chiba, Satoshi Yomoda, Takanori Kawashima, Toshiki Okubo, Yasuhiro TEZUKA, Kenta MURATA